Dupilumab

Moderate-to-severe atopic dermatitis from age six months when topical prescription therapies inadequately control disease or are inadvisable; may use with/without topical corticosteroids. Adult prurigo nodularis and bullous pemphigoid are separate indications. Chronic spontaneous urticaria is labeled from age two in patients symptomatic despite H1 antihistamines; other urticarias are excluded. Respect labeled weight bands rather than extrapolating to smaller children.

Add-on moderate/severe asthma maintenance from age six with eosinophilic phenotype or oral-corticosteroid dependence; add-on inadequately controlled CRSwNP from age 12; adult inadequately controlled COPD with eosinophilic phenotype; AFRS from age six after prior sino-nasal surgery. Eosinophilic esophagitis is labeled from age one and weight ≥15 kg. It does not treat acute bronchospasm/status asthmaticus or acute COPD exacerbations.

Each 600-mg loading dose uses two separate 300-mg injections at different sites; do not inject a doubled volume from one device. Every two weeks means a two-week interval, not twice weekly.

AD age six months–five years and CSU age two–five years use the same below-five-year weight schedule WITHOUT loading. AD/CSU age six–17 use the same older-child loading schedule. The shared table does not erase their different indication ages. For AD, topical calcineurin inhibitors may be reserved for problem areas such as face/folds as the label describes.

Age 6–11: weight 15 to <30 kg, 300 mg every four weeks; ≥30 kg, 200 mg every two weeks; no loading dose. With comorbid moderate/severe AD, use the AD older-child regimen, including loading. Age ≥12 follows the labeled adolescent/adult asthma options; for comorbid AFRS the table’s 600→300-mg option specifically concerns adolescent weight ≥60 kg and adults. Do not infer a loading dose for every young asthma patient.

For EoE at age ≥1: 15 to <30 kg, 200 mg every two weeks; 30 to <40 kg, 300 mg every two weeks; ≥40 kg, 300 mg every week. No loading dose. For AFRS age 6–17 after surgery: 15 to <30 kg, 300 mg every four weeks; 30 to <60 kg, 200 mg every two weeks; ≥60 kg, 300 mg every two weeks. No loading specified for AFRS alone; adults receive 300 mg every two weeks. These bands are not borrowed from AD.

Syringe: age ≥6 months; pen: age ≥2 years. A caregiver administers for children <12; age ≥12 patients may inject under adult supervision after training. Inject thigh or abdomen away from the 5-cm navel area; upper arm if a caregiver injects. Rotate sites and avoid tender/damaged/bruised/scarred skin. Warm naturally with cap on: 300-mg device 45 minutes, 200-mg device 30 minutes. Inspect for particles/discoloration/cloudiness and follow the exact pen/syringe IFU; do not heat, shake, reuse or partially save a device.

Weekly regimen: give as soon as possible and begin a new weekly schedule from that date. Every-two-week or every-four-week regimen: if given within seven days of the missed dose, resume the original schedule; if later, give it and start a new schedule based on that date. Do not use an obsolete rule telling every-two-week users to skip automatically after seven days.

Complete age-appropriate vaccines before treatment when feasible. Keep indicated background asthma/COPD/sinonasal treatment; corticosteroid reductions are gradual and supervised. BP specifically uses an initial tapering oral-steroid course. The label supplies no universal renal/hepatic dose-reduction table and no dose for a child below the indication’s age/weight eligibility.

Known hypersensitivity to dupilumab or any product excipient is the formal contraindication. Eye disease, helminths, vaccine timing and steroid withdrawal are warning/management issues, not automatically added formal contraindications.

The current U.S. Dupixent label has no boxed warning. Its severe hypersensitivity, eye, eosinophilic and other inflammatory warnings still require active follow-up.

Injection-site reactions are common across several indications. Eye inflammation/dryness and herpes infections are prominent in AD; other trial reports vary by disease and include eosinophilia, respiratory symptoms/infections, joint pain and gastrointestinal symptoms. Do not assign one indication’s rates to all users. Serious postmarketing eye, inflammatory and allergic reactions are described. No specific overdose antidote exists: obtain medical/Poison Help advice, monitor adverse symptoms and treat supportively.

Avoid live vaccines during treatment; complete indicated vaccines beforehand where feasible. Evidence for non-live vaccine co-use is limited, rather than a universal contraindication. Do not abruptly discontinue corticosteroids at initiation, and do not independently stop asthma controllers. Other biologics or off-label immunosuppressive combinations are not approved by inference from the mechanism.

Label studies with representative CYP3A4/2C9/2C19/2D6/1A2 substrates found no clinically significant exposure changes, and an effect on co-medication PK is not expected. This limited evidence does not prove every drug combination safe or establish a universal combination regimen. Review each new medicine’s own risks and disease context.

Available pregnancy case reports/series have not identified a drug-associated major-malformation, miscarriage or adverse-outcome signal, but data remain limited; IgG can cross the placenta. Poorly controlled asthma itself carries pregnancy risk. Discuss clinical need and the label’s pregnancy registry. The label has no human milk, infant-effect or milk-production data; balance breastfeeding benefits, maternal need and infant risk rather than claiming milk absence or established safety.

Respect AD ≥6 months, asthma/AFRS ≥6 years, CRSwNP ≥12, EoE ≥1 year and ≥15 kg, CSU ≥2 years and supported weight bands, and adult-only PN/COPD/BP. Syringe versus pen age limits are separate. Older-adult evidence varies across indications; some trials were too small for different-response conclusions. COPD older groups had no overall difference; BP elderly eye/vision findings warrant attention.

The current U.S. label does not provide dedicated severe renal/hepatic studies or a numerical organ-dose algorithm. Antibody catabolism is expected rather than classic CYP/unchanged renal elimination, but this does not prove safety in every severe impairment or justify extrapolated dialysis doses. Individualize complex organ-disease treatment with the specialist.

This human IgG4 monoclonal antibody binds IL-4Rα and inhibits IL-4 and IL-13 signaling through their receptor complexes, affecting type-2 inflammatory pathways. The label states the clinical mechanism is not definitively established. Shared inflammatory pathways do not broaden its approved indications or replace diagnosis.

After an initial subcutaneous dose, peak concentration is reached at approximately one week. Bioavailability is about 61–66%; weight influences exposure. As an IgG4 antibody it is expected to be broken down to peptides/amino acids through catabolic pathways; the full metabolic pathway is not characterized. After the last steady-state dose, adult/adolescent concentrations typically become nondetectable over 9–13 weeks, with longer modeled persistence in younger children. This is not a fixed elimination half-life or permission to extend scheduled intervals.

Confirm diagnosis/eligibility, age/weight, loading need, device, vaccine and helminth history, eye disease and background therapies. Follow disease-specific symptoms/control and corticosteroid taper, adherence and reactions. Promptly evaluate eye symptoms, new skin/joint inflammation and eosinophilic-organ features. Target laboratory or specialist evaluation to the clinical situation; do not invent universal drug levels or mandatory fixed CBC/renal/liver intervals from another immunomodulator.

Explain the prescribed weekly/two-week/four-week schedule, loading injections and current missed-dose rule. Train with the exact device IFU; caregiver use depends on age. Keep rescue inhaler/controller plans, taper steroids only with clinician guidance and review vaccines. Seek urgent help for severe allergy or major vision changes and report worsening lungs, neurologic symptoms, rash or joint pain. Follow cold-chain/14-day limits, never inject a damaged/cloudy device, and use an approved sharps container.

Sanofi–Regeneron Dupixent is clear to slightly opalescent, colorless to pale yellow. Carton of two 300-mg/2-mL prefilled syringes: NDC 0024-5914-01; carton of two 300-mg/2-mL pens: NDC 0024-5915-02. A dose requiring two injections uses two devices, with separate injection sites.

Prefilled syringe and pen each offer 300 mg/2 mL (150 mg/mL) or 200 mg/1.14 mL (175 mg/mL). Both are SC single-dose devices; syringe eligibility starts at six months, pen at two years. Do not confuse concentration with dose or invent IV/oral administration or partial-device dosing.

Refrigerate 2–8°C in original carton protected from light. After removal, use within 14 days at room temperature ≤25°C or discard. Do not freeze, shake, heat or expose to direct sunlight. Warm naturally for 45 minutes (300 mg) or 30 minutes (200 mg), cap still on; inspect before use. Discard unused remainder and place used devices/caps in appropriate sharps disposal according to the IFU/local rules.